TL;DR:
- Pison’s AI technology has the potential to assist in the early detection of ALS.
- Clinical trials demonstrated the ability to detect fasciculations and changes in muscle electrical activity.
- Technology acts as a digital disease biomarker for ALS, allowing for earlier treatment initiation and remote monitoring.
- Works by measuring electrical signals from the brain through motor neurons
- Weakened electrical signals from the brain caused by ALS help algorithms distinguish ALS patients from healthy individuals.
- Pison plans to incorporate the technology into wearable devices for passive health monitoring.
- Larger studies are planned to validate technology’s ability to diagnose and monitor the progression of ALS and other neurodegenerative diseases
- The ALS Association recognizes the importance of finding new ways to diagnose and monitor patients with ALS.
Main AI News:
A cutting-edge technology developed by Pison has the potential to revolutionize the early detection of Amyotrophic Lateral Sclerosis (ALS). In a recent clinical trial, the AI technology demonstrated its ability to detect fasciculations, involuntary muscle twitches, and changes in muscle electrical activity, offering a significant advantage in early diagnosis and treatment of the disease.
The technology acts as a digital disease biomarker for ALS, allowing for earlier treatment initiation when the disease is more responsive to intervention. It also provides doctors with a means of monitoring patients’ progress and determining the efficacy of treatment.
“If these results are validated, it will enable clinicians to detect motor neuron involvement non-invasively and track it over the course of the disease and treatment interventions,” said Terry Heiman-Patterson, the lead investigator of the study and Professor of Neurology.
The technology works by measuring electrical signals from the brain through specialized nerve cells called motor neurons. These signals can be captured via electroneurography, a technique that uses a set of electrodes in contact with the skin. Pison’s neural biosensor, worn on the wrist, contains electrodes similar to those used in electroneurography but allows for round-the-clock recording of electrical signals. The machine learning algorithms then convert the recordings into information that can be understood by computers.
The weakening of electrical signals from the brain, a result of motor neuron damage caused by ALS, helps the algorithms distinguish ALS patients from healthy individuals, even before symptoms of ALS are present.
“This technique may enable earlier diagnosis of motor neuron damage in presymptomatic gene carriers, help detect motor neuron involvement in other disorders, and provide a system for remotely monitoring progression in ALS and aiding in patient-centric clinical trial design,” said Heiman-Patterson, who also serves as the Director of the MDA/ALS Center of Hope at Temple University.
Incorporating AI into Wearables to Revolutionize ALS Diagnosis and Monitoring
Pison is working on integrating its AI technology into wearable devices, such as fitness trackers and smartwatches, to provide patients with ALS with remote monitoring benefits. The technology has the potential to change the way doctors diagnose and monitor the disease, providing them with valuable information about patients’ motor neuron health and allowing for early detection of the condition.
Pison has started licensing its neural biosensor for integration into popular wearables, such as smartwatches and fitness trackers, for passive health monitoring. This will allow for tracking of ALS and other neurological disorders through neural health apps and telehealth services. The ALS Association, together with the National Science Foundation, recognizes the need for new and better ways to diagnose and monitor patients with ALS.
Pison is planning to conduct larger and longer studies to validate the technology’s ability to diagnose and monitor the progression of ALS and other neurodegenerative diseases, such as multiple sclerosis and Parkinson’s disease. These studies will contribute to establishing the technology as a reliable and effective tool for the diagnosis and management of these conditions.
Conlcusion:
Pison’s AI technology presents a major milestone for the medical sector, presenting a cutting-edge solution for the early detection and monitoring of ALS and other neurodegenerative conditions. The technology’s potential to be integrated into wearable devices, such as smartwatches and fitness trackers, opens up new avenues for passive health monitoring and remote patient management.
The endorsement of the technology’s significance by the ALS Association and the National Science Foundation, along with Pison’s plans to conduct further studies, are all indicators of the technology’s potential impact in the healthcare market. Overall, Pison’s AI technology could be a game-changer in the field of early disease detection and management.
